Patents by Inventor Elena Orlando

Elena Orlando has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11069583
    Abstract: A plurality of endpoints in a wet etching process of a substrate are determined. A plurality of benchmark end points during a wet etching process of a first substrate are determined, using first light information represented by a HSV color model for sample locations of the first substrate. Etch parameters are generated for a wet etching process for a second substrate. The generated etch parameters are used with second light information represented by at least one value of the Hue, Saturation, Value color model associated with a plurality of sample locations of the second substrate to reach respective end points during the wet etching process of a second substrate.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: July 20, 2021
    Assignee: VEECO INSTRUMENTS INC.
    Inventors: John Taddei, David A. Goldberg, Elena Lawrence, Ian Cochran, Christopher Orlando, James Swallow, William Gilbert Breingan
  • Publication number: 20210213063
    Abstract: The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule in combination with a BTK inhibitor.
    Type: Application
    Filed: May 24, 2019
    Publication date: July 15, 2021
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Randi Isaacs, K. Gary J. Vanasse, Eric Bleickardt, Saar Gill, Marco Ruella, Nathan Amar Singh, Elena Orlando
  • Publication number: 20210172020
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 10, 2021
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael C. Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20200370012
    Abstract: The disclosure provides methods of making CAR-expressing immune effector cells (e.g., T cells, or NK cells), and compositions and reaction mixtures comprising the same. The disclosure further provides methods of using said CAR-expressing immune effector cells.
    Type: Application
    Filed: October 25, 2018
    Publication date: November 26, 2020
    Inventors: Joseph A. Fraietta, Jan J. Melenhorst, Elena Orlando, Roderick O'Connor, Carl H. June
  • Patent number: 10774388
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: September 15, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20190292238
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: January 24, 2019
    Publication date: September 26, 2019
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Patent number: 10253086
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 9, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Publication number: 20170306416
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishnek Garg, David Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20160362472
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 8, 2016
    Publication date: December 15, 2016
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou